Shots:

• The P-III IMspire150 study involves assessing of Tecentriq (atezolizumab) + Cotellic (cobimetinib) + Zelboraf (vemurafenib) vs PBO+ Cotellic + Zelboraf in patients with previously untreated BRAF V600 mutation-positive advanced melanoma
• The P-III IMspire150 study results: reduction in risk of disease worsening or death; improvement in PFS; consistent safety profile with the known profile of individual therapies
• Cotellic is a MEK1/2 inhibitor while Zelboraf is a prescription therapy indicated to treat melanoma that has spread to other parts of the body or cannot be removed by surgery and has BRAF V600 mutation. Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor

Click here to­ read full press release/ article 

 Ref: Roche | Image: Roche